HDAC9 and cancer: With the increasing interest in HDAC inhibitors as potential cancer therapeutics, the anti-cancer activity of domatinostat, a novel class I-selective HDAC inhibitor, has been actively explored in the past several years and has been demonstrated in cancer cells from solid tumors as well as hematological malignancies.